Monoclonal Antibody to Lectin Galactoside Binding, Soluble 3 Binding Protein (LGALS3BP)
| Code | Size | Price |
|---|
| MAB766Hu22-20ul | 20ul | £87.00 |
Quantity:
| MAB766Hu22-100ul | 100ul | £162.00 |
Quantity:
| MAB766Hu22-200ul | 200ul | £219.00 |
Quantity:
| MAB766Hu22-1ml | 1ml | £502.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
MAC-2-BP; LGALS3-BP; Galectin-3-Binding Protein; L3 Antigen; Mac-2-Binding Protein; Tumor-associated antigen 90K; Serum Protein 90K; Basement membrane autoantigen p105
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Lectin Galactoside Binding, Soluble 3 Binding Protein
Potency (Clone Number):
D5
Reactivity:
Ra;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-3ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Lectin Galactoside Binding, Soluble 3 Binding Protein (LGALS3BP) | RPB766Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||